Showing 1 - 8 results of 8 for search 'Peihao Zheng', query time: 0.03s Refine Results
  1. 1
    Characteristics and prognosis of rrDLBCL with TP53 mutations and a high‐risk subgroup represented by the co‐mutations of DDX3X‐TP53

    Characteristics and prognosis of rrDLBCL with TP53 mutations and a high‐risk subgroup represented by the co‐mutations of DDX3X‐TP53 by Fan Gao, Kai Hu, Peihao Zheng, Hui Shi, Xiaoyan Ke

    Published 2023-05-01
    Get full text
    Article
  2. 2
    Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing

    Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing by Fan Gao, Lei Tian, Hui Shi, Peihao Zheng, Jing Wang, Fei Dong, Kai Hu, Xiaoyan Ke

    Published 2021-12-01
    Get full text
    Article
  3. 3
    P1195: A PROSPECTIVE STUDY OF TARGETED SEQUENTIAL IMMUNOTHERAPY. IN PATIENTS WITH RELAPSED REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA.

    P1195: A PROSPECTIVE STUDY OF TARGETED SEQUENTIAL IMMUNOTHERAPY. IN PATIENTS WITH RELAPSED REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA. by Yuelu Guo, Kai Hu, Xiaoyan Ke, Teng Xu, Shaomei Feng, Peihao Zheng, Lixia MA, Fan Yang, Hui Shi, Biping Deng, Liu Rui, Zhonghua Fu

    Published 2023-08-01
    Get full text
    Article
  4. 4
    PB2101: A PROSPECTIVE INVESTIGATION INTO THE TIMING AND STATUS OF BCMA-CART IN SECONDARY PLASMA CELL LEUKEMIA

    PB2101: A PROSPECTIVE INVESTIGATION INTO THE TIMING AND STATUS OF BCMA-CART IN SECONDARY PLASMA CELL LEUKEMIA by Yuelu Guo, Kai Hu, Xiaoyan Ke, Fan Yang, Lixia MA, Teng Xu, Liu Rui, Zhonghua Fu, Peihao Zheng, Shaomei Feng, Hui Shi, Biping Deng

    Published 2023-08-01
    Get full text
    Article
  5. 5
    P1168: DURABLE REMISSION AFTER SEQUENTIAL CD19/20 CAR T-CELL “CAKE-ICING” THERAPY OCCURRED IN REFRACTORY/RELAPSED DLBCL

    P1168: DURABLE REMISSION AFTER SEQUENTIAL CD19/20 CAR T-CELL “CAKE-ICING” THERAPY OCCURRED IN REFRACTORY/RELAPSED DLBCL by Peihao Zheng, Fei Xue, Fan Yang, Shaomei Feng, Yuelu Guo, Hui Shi, Guoai Su, Lixia MA, Liu Rui, Biping Deng, Kai Hu, Xiaoyan Ke

    Published 2023-08-01
    Get full text
    Article
  6. 6
    P1173: EARLY ADMINISTRATION OF POLATUZUMAB VEDOTIN AS BRIDGING CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IS AN EFFECTIVE STRATEGY TO IMPROVE SURVIVAL IN PATIENTS WITH R/R B-CELL LYMPHOMA

    P1173: EARLY ADMINISTRATION OF POLATUZUMAB VEDOTIN AS BRIDGING CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IS AN EFFECTIVE STRATEGY TO IMPROVE SURVIVAL IN PATIENTS WITH... by Fan Yang, Rui Liu, Zhonghua Fu, Teng Xu, Peihao Zheng, Shaomei Feng, Yuelu Guo, Lixia MA, Hui Shi, Biping Deng, Xiaoyan Ke, Kai Hu

    Published 2023-08-01
    Get full text
    Article
  7. 7
    PB2333: CAR-T CELL THERAPY IS A EXCELLENT STRATEGY FOR R/R B-NHL

    PB2333: CAR-T CELL THERAPY IS A EXCELLENT STRATEGY FOR R/R B-NHL by Liu Rui, Fan Yang, Fei Xue, Hui Shi, Peihao Zheng, Lixia MA, Shaomei Feng, Yuelu Guo, Teng Xu, Zhonghua Fu, Biping Deng, Xiaoyan Ke, Kai Hu

    Published 2023-08-01
    Get full text
    Article
  8. 8
    PB2326: OUTCOMES OF ANTI-CANCER THERAPY IN PATIENTS WITH PROGRESSIVE REFRACTORY/RELAPSED B-CELL LYMPHOMA DURING SEVERE CORONAVIRUS DISEASE 2019 (COVID-19): A REAL-WORLD STUDY FROM CHINA

    PB2326: OUTCOMES OF ANTI-CANCER THERAPY IN PATIENTS WITH PROGRESSIVE REFRACTORY/RELAPSED B-CELL LYMPHOMA DURING SEVERE CORONAVIRUS DISEASE 2019 (COVID-19): A REAL-WORLD STUDY FROM... by Guoai Su, Kai Hu, Xiaoyan Ke, Hui Shi, Peihao Zheng, Fan Yang, Shaomei Feng, Yuelu Guo, Liaxia MA, Fei Xue, Liu Rui, Teng Xu, Zhonghua Fu, Biping Deng

    Published 2023-08-01
    Get full text
    Article

Search Tools: